'Vive la Résistance!' - the PI3K-Akt pathway can determine target sensitivity to regulatory T cell suppression

Trends in Immunology

Volumn 28, Issue 4, 2007, Pages 154-160

  Wohlfert, Elizabeth A ^a   Clark, Robert B ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; AUTOIMMUNITY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GENE TARGETING; GENETIC ENGINEERING; IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ENZYME ACTIVATION; HUMANS; IMMUNOSUPPRESSION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 33947496068     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.02.003     Document Type: Article

References (44)

1. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25 (2006) 195-201
2. -/- mice. J. Immunol. 173 (2004) 1059-1065
3. + regulatory T cells. J. Exp. Med. 201 (2005) 181-187
4. + regulatory T cells. J. Exp. Med. 201 (2005) 737-746
5. + regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum. 52 (2005) 1180-1184
6. You S., et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54 (2005) 1415-1422
7. King C.G., et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat. Med. 12 (2006) 1088-1092
8. Loskog A., et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20 (2006) 1819-1828
9. Gregori S., et al. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J. Immunol. 171 (2003) 4040-4047
10. Wohlfert E.A., et al. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-β sensitivity in vitro and in vivo. J. Immunol. 176 (2006) 1316-1320
11. Bachmaier K., et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403 (2000) 211-216
12. Chiang Y.J., et al. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403 (2000) 216-220
13. Heissmeyer V., et al. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat. Immunol. 5 (2004) 255-265
14. Jeon M.S., et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21 (2004) 167-177
15. Fang D., and Liu Y.C. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat. Immunol. 2 (2001) 870-875
16. + regulatory T cells. J. Immunol. 171 (2003) 3348-3352
17. Gorelik L., and Flavell R.A. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12 (2000) 171-181
18. Ranger A.M., et al. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 9 (1998) 627-635
19. H cells. Nat. Immunol. 3 (2002) 48-54
20. Ye H., et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418 (2002) 443-447
21. Ohashi P.S., and Yeh W.C. Supressing the supressors. Nat. Med. 12 (2006) 1000-1002
22. Koyasu S. The role of PI3K in immune cells. Nat. Immunol. 4 (2003) 313-319
23. Fruman D.A. Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. Curr. Opin. Immunol. 16 (2004) 314-320
24. +/- mice. Science 285 (1999) 2122-2125
25. Borlado L.R., et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14 (2000) 895-903
26. Suzuki A., et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14 (2001) 523-534
27. Parsons M.J., et al. Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. J. Immunol. 167 (2001) 42-48
28. Ohashi P.S. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat. Rev. Immunol. 2 (2002) 427-438
29. Rathmell J.C., et al. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol. 33 (2003) 2223-2232
30. + T cell suppressor function. J. Immunol. 172 (2004) 6519-6523
31. Tang Q., et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 7 (2006) 83-92
32. +high regulatory T cell function. J. Immunol. 169 (2002) 6210-6217
33. George T.C., et al. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur. J. Immunol. 33 (2003) 502-511
34. Cuevas B., et al. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J. Biol. Chem. 274 (1999) 27583-27589
35. Latchman Y., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2 (2001) 261-268
36. Parry R.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25 (2005) 9543-9553
37. Cinek T., et al. Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4. J. Immunol. 164 (2000) 5-8
38. + regulatory T cells is not essential for suppression of intestinal inflammation. Eur. J. Immunol. 35 (2005) 2886-2895
39. Conery A.R., et al. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β induced apoptosis. Nat. Cell Biol. 6 (2004) 366-372
40. Remy I., et al. PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3. Nat. Cell Biol. 6 (2004) 358-365
41. Atfi A., et al. Bcr-Abl activates the AKT/FoxO3 signalling pathway to restrict transforming growth factor-β-mediated cytostatic signals. EMBO Rep. 6 (2005) 985-991
42. Qiao J., et al. Inhibition of transforming growth factor-β/Smad signaling by phosphatidylinositol 3-kinase pathway. Cancer Lett. 242 (2006) 207-214
43. Song K., et al. Novel roles of Akt and mTOR in suppressing TGF-β/ALK5-mediated Smad3 activation. EMBO J. 25 (2006) 58-69
44. Sun T., et al. Protein tyrosine phosphatase 1B regulates TGFβ1-induced Smad2 activation through PI3 kinase-dependent pathway. Cytokine 35 (2006) 88-94